Skip to main content

Bender Jeremy's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Aug 19, 2024

Accession no.
0001415889-24-021617
Filed
Aug 19, 2024
Trade date
Aug 15-16, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $149.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bender JeremyCIK 0001863107Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2024Common StockMOption exerciseAcquired+3,562––93,176Direct
Aug 15, 2024Common StockMOption exerciseAcquired+4,750––97,926Direct
Aug 15, 2024Common StockMOption exerciseAcquired+11,687––109,613Direct
Aug 16, 2024Common StockSSaleDisposed−10,681$14.00−$149,53498,932Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 15, 2024Common StockMOption exerciseDisposed−3,562$0.00$017,818Direct
Aug 15, 2024Common StockMOption exerciseDisposed−4,750$0.00$042,750Direct
Aug 15, 2024Common StockMOption exerciseDisposed−11,687$0.00$0151,939Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)